印度乳腺癌患者的10年生存率。

Q1 Environmental Science
Journal of Carcinogenesis Pub Date : 2021-03-16 eCollection Date: 2021-01-01 DOI:10.4103/jcar.JCar_26_20
Patel Viral, K Pavithran, K Beena, Ajil Shaji, D K Vijaykumar
{"title":"印度乳腺癌患者的10年生存率。","authors":"Patel Viral,&nbsp;K Pavithran,&nbsp;K Beena,&nbsp;Ajil Shaji,&nbsp;D K Vijaykumar","doi":"10.4103/jcar.JCar_26_20","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Breast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent.</p><p><strong>Materials and methods: </strong>This is a retrospective cohort analysis of 1301 breast cancer patients of all stages who had received primary treatment with curative intent from 2004 to 2010 at a single cancer institution of India.</p><p><strong>Results: </strong>A total of 1301 breast cancer patients were available for final analysis. The median age was 51 years (range, 21-86 years). 70.25% of the patients had early breast cancer (EBC), 21.9% had locally advanced breast cancer, and 7.85% of the patients with de novo metastatic disease also underwent surgery. 56.5% of the patients had hormone-sensitive tumors, human epidermal growth factor receptor 2 over expression was seen in 17%, and triple-negative tumors accounted for 26.2% of the patients. The 5- and 10-year overall survival (OS) of the entire cohort was 79% and 66%, and the 5- and 10-year breast cancer-specific survival (BCSS) was 79% and 70%, respectively. OS and BCSS were 51% and 58%, respectively, at 15-year follow-up after primary cancer treatment. On multivariate analysis, the factors associated with prolonged survival were age ≤50 years, EBC, and treatment during the later period (2008-2010).</p><p><strong>Conclusion: </strong>Difference between OS and BCSS was found to have an increasing trend during 10-15-year follow-up, the difference being 4% at 10 years and 7% at 15 years. Age ≤50 years, early-stage disease at presentation, and primary cancer treatment in later years (2008-2010) were favorable predictors for 10-year survival.</p>","PeriodicalId":52464,"journal":{"name":"Journal of Carcinogenesis","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202444/pdf/","citationCount":"7","resultStr":"{\"title\":\"Ten-year survival outcome of breast cancer patients in India.\",\"authors\":\"Patel Viral,&nbsp;K Pavithran,&nbsp;K Beena,&nbsp;Ajil Shaji,&nbsp;D K Vijaykumar\",\"doi\":\"10.4103/jcar.JCar_26_20\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Breast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent.</p><p><strong>Materials and methods: </strong>This is a retrospective cohort analysis of 1301 breast cancer patients of all stages who had received primary treatment with curative intent from 2004 to 2010 at a single cancer institution of India.</p><p><strong>Results: </strong>A total of 1301 breast cancer patients were available for final analysis. The median age was 51 years (range, 21-86 years). 70.25% of the patients had early breast cancer (EBC), 21.9% had locally advanced breast cancer, and 7.85% of the patients with de novo metastatic disease also underwent surgery. 56.5% of the patients had hormone-sensitive tumors, human epidermal growth factor receptor 2 over expression was seen in 17%, and triple-negative tumors accounted for 26.2% of the patients. The 5- and 10-year overall survival (OS) of the entire cohort was 79% and 66%, and the 5- and 10-year breast cancer-specific survival (BCSS) was 79% and 70%, respectively. OS and BCSS were 51% and 58%, respectively, at 15-year follow-up after primary cancer treatment. On multivariate analysis, the factors associated with prolonged survival were age ≤50 years, EBC, and treatment during the later period (2008-2010).</p><p><strong>Conclusion: </strong>Difference between OS and BCSS was found to have an increasing trend during 10-15-year follow-up, the difference being 4% at 10 years and 7% at 15 years. Age ≤50 years, early-stage disease at presentation, and primary cancer treatment in later years (2008-2010) were favorable predictors for 10-year survival.</p>\",\"PeriodicalId\":52464,\"journal\":{\"name\":\"Journal of Carcinogenesis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202444/pdf/\",\"citationCount\":\"7\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Carcinogenesis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4103/jcar.JCar_26_20\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Environmental Science\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Carcinogenesis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jcar.JCar_26_20","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Environmental Science","Score":null,"Total":0}
引用次数: 7

摘要

简介:乳腺癌是印度女性中最常见的癌症;然而,没有关于长期生存(10年及以上)的研究。本研究旨在评估接受治疗的乳腺癌患者的长期肿瘤预后。材料和方法:这是一项回顾性队列分析,对2004年至2010年在印度一家癌症机构接受过有治愈意图的初级治疗的1301名各阶段乳腺癌患者进行分析。结果:共有1301例乳腺癌患者进行最终分析。中位年龄为51岁(范围21-86岁)。70.25%的患者早期乳腺癌(EBC), 21.9%的患者局部晚期乳腺癌,7.85%的新发转移性乳腺癌患者也进行了手术。激素敏感性肿瘤占56.5%,人表皮生长因子受体2过表达占17%,三阴性肿瘤占26.2%。整个队列的5年和10年总生存率(OS)分别为79%和66%,5年和10年乳腺癌特异性生存率(BCSS)分别为79%和70%。原发性癌症治疗后15年随访时,OS和BCSS分别为51%和58%。在多变量分析中,与延长生存期相关的因素是年龄≤50岁、EBC和后期(2008-2010年)的治疗。结论:10-15年随访中,OS与BCSS的差异有增加趋势,10年差异为4%,15年差异为7%。年龄≤50岁、发病时处于早期阶段以及晚期(2008-2010年)的原发性癌症治疗是10年生存率的有利预测因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。

Ten-year survival outcome of breast cancer patients in India.

Ten-year survival outcome of breast cancer patients in India.

Ten-year survival outcome of breast cancer patients in India.

Ten-year survival outcome of breast cancer patients in India.

Introduction: Breast cancer is the most frequently diagnosed cancer among women in India; however, there are no studies addressing long-term survival (10 years and above). This study sought to evaluate long-term oncological outcome among women with breast cancer treated with a curative intent.

Materials and methods: This is a retrospective cohort analysis of 1301 breast cancer patients of all stages who had received primary treatment with curative intent from 2004 to 2010 at a single cancer institution of India.

Results: A total of 1301 breast cancer patients were available for final analysis. The median age was 51 years (range, 21-86 years). 70.25% of the patients had early breast cancer (EBC), 21.9% had locally advanced breast cancer, and 7.85% of the patients with de novo metastatic disease also underwent surgery. 56.5% of the patients had hormone-sensitive tumors, human epidermal growth factor receptor 2 over expression was seen in 17%, and triple-negative tumors accounted for 26.2% of the patients. The 5- and 10-year overall survival (OS) of the entire cohort was 79% and 66%, and the 5- and 10-year breast cancer-specific survival (BCSS) was 79% and 70%, respectively. OS and BCSS were 51% and 58%, respectively, at 15-year follow-up after primary cancer treatment. On multivariate analysis, the factors associated with prolonged survival were age ≤50 years, EBC, and treatment during the later period (2008-2010).

Conclusion: Difference between OS and BCSS was found to have an increasing trend during 10-15-year follow-up, the difference being 4% at 10 years and 7% at 15 years. Age ≤50 years, early-stage disease at presentation, and primary cancer treatment in later years (2008-2010) were favorable predictors for 10-year survival.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Journal of Carcinogenesis
Journal of Carcinogenesis Environmental Science-Health, Toxicology and Mutagenesis
CiteScore
7.50
自引率
0.00%
发文量
0
审稿时长
15 weeks
期刊介绍: Journal of Carcinogenesis considers manuscripts in many areas of carcinogenesis and Chemoprevention. Primary areas of interest to the journal include: physical and chemical carcinogenesis and mutagenesis; processes influencing or modulating carcinogenesis, such as DNA repair; genetics, nutrition, and metabolism of carcinogens; the mechanism of action of carcinogens and modulating agents; epidemiological studies; and, the formation, detection, identification, and quantification of environmental carcinogens. Manuscripts that contribute to the understanding of cancer prevention are especially encouraged for submission
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信